nach oben

Current Fungal Infection Reports

Erschienen in:

01.03.2013 | Pediatric Fungal Infections (T Lehrnbecher, Section Editor)

The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children

verfasst von: Brian T. Fisher

Erschienen in: Current Fungal Infection Reports | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Invasive aspergillosis (IA) is a feared opportunistic infection for many immuncompromised children resulting in significant morbidity and mortality. Timely diagnosis based on traditional testing modalities and clinical evaluation has proven to be challenging. Assays designed to measure IA biomarkers such as galactomannan (GM) and beta-D-glucan (BG) represent a potential significant improvement in the ability to diagnose pediatric IA. However, as with any new diagnostic tool, clinicians need to be aware of the operating characteristics of these assays in order to apply them in the appropriate settings. Published adult and pediatric data regarding GM and BG testing are reviewed and guidance regarding the appropriate utility of these assays in children is offered.

• Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121:e1286–94. This manuscript represents one of the largest collections of pediatric patients with invasive aspergillosis and describes important case characteristics and their outcomes.PubMedCrossRef

Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006;117:e711–6.PubMedCrossRef

Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608–15.PubMedCrossRef

von Eiff M, Roos N, Schulten R, Hesse M, Zühlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995;62:341–7.CrossRef

Ascioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7–14.PubMedCrossRef

Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004;190:641–9.PubMedCrossRef

Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199–205.PubMedCrossRef

Ellis M, Al-Ramadi B, Finkelman M, et al. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol. 2008;57:287–95.PubMedCrossRef

Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604–10.PubMedCrossRef

10.

Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42:1417–27.PubMedCrossRef

11.

•• Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev. 2008; CD007394. This is a meta-analysis of the studies investigating galactomannan testing in immunocompromised patients. Importantly this publication represents mostly adult patient populations.

12.

De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.PubMedCrossRef

13.

Lehmann PF, Reiss E. Invasive aspergillosis: antiserum for circulating antigen produced after immunization with serum from infected rabbits. Infect Immun. 1978;20:570–2.PubMed

14.

Reiss E, Lehmann PF. Galactomannan antigenemia in invasive aspergillosis. Infect Immun. 1979;25:357–65.PubMed

15.

Kurup VP, Kumar A. Immunodiagnosis of aspergillosis. Clin Microbiol Rev. 1991;4:439–56.PubMed

16.

Stynen D, Sarfati J, Goris A, et al. Rat monoclonal antibodies against Aspergillus galactomannan. Infect Immun. 1992;60:2237–45.PubMed

17.

Stynen D, Goris A, Sarfati J, Latge JP. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol. 1995;33:497–500.PubMed

18.

Verweij PE, Stynen D, Rijs AJ, de Pauw BE, Hoogkamp-Korstanje JA, Meis JF. Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol. 1995;33:1912–4.PubMed

19.

Armenian SH, Nash KA, Kapoor N, et al. Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. J Pediatr Hematol Oncol. 2009;31:920–6.PubMedCrossRef

20.

Fisher BT, Zaoutis TE, Park JR, et al. Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. Journal of the Pediatric Infectious Diseases Society. 2012;1:103–11.CrossRef

21.

Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J. 1996;15:232–7.PubMedCrossRef

22.

Sulahian A, Boutboul F, Ribaud P, Leblanc T, Lacroix C, Derouin F. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer. 2001;91:311–8.PubMedCrossRef

23.

Hovi L, Saxen H, Saarinen-Pihkala UM, Vettenranta K, Meri T, Richardson M. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer. 2007;48:28–34.PubMedCrossRef

24.

Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J. 2007;26:558–64.PubMedCrossRef

25.

Fisher BT, Harris T, Torp K, et al. Establishment of an 11-Year Cohort of 8733 Pediatric Patients Hospitalized at United States Free-standing Children's Hospitals With De Novo Acute Lymphoblastic Leukemia From Health Care Administrative Data. Med Care 2012; epub ahead of print.

26.

•• Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology. 2012; epub ahead of print. This manuscript is the first pediatric fever and neutropenia guideline. It summarizes the impact of both galactomannan and beta glucan testing in children.

27.

Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40:1762–9.PubMedCrossRef

28.

Verweij PE, Weemaes CM, Curfs JH, Bretagne S, Meis JF. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol. 2000;38:3900–1.PubMed

29.

Mortensen KL, Knudsen JB, Jensen-Fangel S, Stausbøl-Grøn B, Arendrup MC, Petersen E. Successful management of invasive aspergillosis presenting as pericarditis in an adult patient with chronic granulomatous disease. Mycoses. 2011;54:e233–6.PubMedCrossRef

30.

Falcone EL, Holland SM. Invasive fungal infection in chronic granulomatous disease: insights into pathogenesis and management. Curr Opin Infect Dis. 2012;25:658–69.PubMedCrossRef

31.

Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia™ Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant. 2004;4:796–802.PubMedCrossRef

32.

Kwak EJ, Husain S, Obman A, et al. Efficacy of galactomannan antigen in the Platelia™ Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol. 2004;42:435–8.PubMedCrossRef

33.

Fortún J, Martín-Dávila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 2002;8:1065–70.PubMedCrossRef

34.

Cornet M, Mallat H, Somme D, et al. Fulminant invasive pulmonary aspergillosis in immunocompetent patients–a two-case report. Clin Microbiol Infect. 2003;9:1224–7.PubMedCrossRef

35.

Gangneux JP, Camus C, Philippe B. Epidemiology of invasive aspergillosis and risk factors in non neutropaenic patients. Rev Mal Respir. 2010;27:e34–46.PubMedCrossRef

36.

Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009;49:1688–93.PubMedCrossRef

37.

Desai R, Ross LA, Hoffman JA. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr Infect Dis J. 2009;28:283–6.PubMedCrossRef

38.

Tabarsi P, Soraghi A, Marjani M, et al. Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients. Exp Clin Transplant. 2012;10:278–81.PubMedCrossRef

39.

Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation. 2007;83:1330–6.PubMedCrossRef

40.

Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol. 2007;45:1759–65.PubMedCrossRef

41.

Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol. 2002;40:1496–9.PubMedCrossRef

42.

Roilides E, Pavlidou E, Papadopoulos F, et al. Cerebral aspergillosis in an infant with corticosteroid-resistant nephrotic syndrome. Pediatr Nephrol. 2003;18:450–3.PubMed

43.

Nouér SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, Anaissie E. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis. 2011;53:671–6.PubMedCrossRef

44.

Bergeron A, Porcher R, Menotti J, et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol. 2012;50:823–30.PubMedCrossRef

45.

Chai LYA, Kullberg BJ, Johnson EM, et al. Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol. 2012;50:2330–6.PubMedCrossRef

46.

Marty FM, Koo S. Role of (1–>3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol. 2009;47 Suppl 1:S233–40.PubMedCrossRef

47.

Levin J, Bang FB. Clottable protein in Limulus; its localization and kinetics of its coagulation by endotoxin. Thrombosis et diathesis haemorrhagica. 1968;19:186–97.PubMed

48.

Morita T, Tanaka S, Nakamura T, Iwanaga S. A new (1-3)-b-D-glucan-mediated coagulation pathway found inLimulusamebocytes. FEBS Lett. 1981;129:318–21.CrossRef

49.

Obayashi T, Tamura H, Tanaka S, et al. A new chromogenic endotoxin-specific assay using recombined limulus coagulation enzymes and its clinical applications. Clinica chimica acta; international journal of clinical chemistry. 1985;149:55–65.PubMedCrossRef

50.

• Smith PB, Benjamin DK, Alexander BD, Johnson MD, Finkelman MA, Steinbach WJ. Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol. 2007;14:924–5. This manuscript questions the appropriate threshold level for beta glucan testing in children.PubMedCrossRef

51.

Zhao L, Tang J-Y, Wang Y, et al. Value of plasma beta-Glucan in early diagnosis of invasive fungal infection in children. Chin J Contemp Pediatr. 2009;11:905–8.

52.

Mularoni A, Furfaro E, Faraci M, et al. High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol. 2010;17:882–3.PubMedCrossRef

53.

Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR. Reactivity of (1–>3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother. 2006;50:3450–3.PubMedCrossRef

54.

Wheat LJ, Walsh TJ. Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis. 2008;27:245–51.PubMedCrossRef

55.

• Mikulska M, Furfaro E, Del Bono V, et al. Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother. 2012;67:1746–8. This manuscript presents data that exonerates piperacillin/tazobactam as a cause for false positive galactomannan testing. This is important as piperacillin/tazobactam has long been implicated as a contributor to false positivity.PubMedCrossRef

56.

Gerlinger MP, Rousselot P, Rigaudeau S, et al. False positive galactomannan Platelia due to piperacillin-tazobactam. Med Mal Infect. 2012;42:10–4.PubMedCrossRef

57.

Metan G, Agkus C, Nedret Koc A, Elmali F, Finkelman MA. Does ampicillin-sulbactam cause false positivity of (1,3)-beta-D-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections. Mycoses. 2012;55:366–71.PubMedCrossRef

58.

Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52:750–70.PubMedCrossRef

59.

• Cordonnier C, Pautas C, Maury S, et al. Empirical versus Preemptive Antifungal Therapy for High–Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial. Clin Infect Dis. 2009;48:1042–51. This manuscript presents a controlled comparison of two therapeutic options for antifungal therapy in patients with fever and neutropenia.PubMedCrossRef

60.

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–31.PubMedCrossRef

61.

Pagano L, Caira M, Nosari A, et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica. 2011;96:1366–70.PubMedCrossRef

62.

Klingspor L, Loeffler J. Aspergillus PCR formidable challenges and progress. Med Mycol. 2009;47 Suppl 1:S241–7.PubMedCrossRef

63.

Badiee P, Alborzi A, Karimi M, et al. Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients. J Infect Dev Ctries. 2012;6:352–7.PubMedCrossRef

64.

Teutschbein J, Albrecht D, Pötsch M, et al. Proteome profiling and functional classification of intracellular proteins from conidia of the human-pathogenic mold Aspergillus fumigatus. J Proteome Res. 2010;9:3427–42.PubMedCrossRef

65.

Kniemeyer O, Lessing F, Brakhage AA. Proteome analysis for pathogenicity and new diagnostic markers for Aspergillus fumigatus. Med Mycol. 2009;47 Suppl 1:S248–54.PubMedCrossRef

Titel: The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children
verfasst von: Brian T. Fisher
Publikationsdatum: 01.03.2013
Verlag: Current Science Inc.
Erschienen in: Current Fungal Infection Reports / Ausgabe 1/2013
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-012-0127-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Penicillium marneffei Infection in Immunocompromised Host

1–3 β-D-glucan: From Diagnosis to Prognosis

Are Echinocandins Better Than Azoles for Invasive Candidiasis?

How I Treat Coccidioidomycosis

Advancing the Field: Evidence for New Management Strategies in Invasive Fungal Infections

How I Treat Histoplasmosis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin